Smith+Nephew Academy Expands Global Access to Professional Medical Education Through Virtual Reality and Other Advanced Simulation Technologies

0

[ad_1]

LONDON , September 21, 2022 /PRNewswire/ — Smith+Nephew (LSE: SN, NYSE:SNN), the global medical technology company, today announces that it is expanding the scope of its medical education program with a suite of advanced simulation technologies. Healthcare professionals can now easily access basic procedural skills training in orthopaedics, robotics and sports medicine using virtual and augmented reality, haptics and 3D interactive games across all Centers of Excellence from Smith+Nephew Academy around the world.

Healthcare professionals universally recognize the benefits that simulation technology can provide as part of their continuing education journey. Building procedural, psychomotor, and cognitive skills by simulating a surgeon’s decision-making process provides an immersive learning experience that traditional training methods cannot match.

Mr. Stephen Mitchell, trauma consultant and orthopedic surgeon at Bristol University Hospitals NHS Foundation Trust recently led a course in hip fracture management for Smith + Nephew using virtual reality. He commented: “Virtual reality offers a huge opportunity for future training applications to drive both an accelerated learning process and distance learning. It lends itself perfectly to the 2D/3D nature of trauma, arthroscopy and arthroplasty procedures.

Recent randomized controlled trials have generated data that indicate virtual reality training programs may be a more effective modality of learning orthopedic surgical techniques compared to passive learning tools such as standard guide training.1 Training groups completed their assessments faster, with a higher overall assessment score, and demonstrated greater retention with higher scores on a two-week retest.1

A recent Smith+Nephew survey of attendees of a virtual reality training course concluded that they felt the workshop increased their knowledge of surgical procedures and better prepared them for the cadaver lab through the guided tour of instrumentation.2 When asked if they would like to see more virtual reality sessions in future medical education programs, 90% of participants said “yes”.2

“Smith+Nephew’s commitment to being a global leader in medical education and improving patient outcomes is essential to providing a state-of-the-art, interactive learning environment tailored to the needs of healthcare professionals. health,” said Cindy Walker, senior vice president of global medical education for Smith+Nephew. “With Smith+Nephew Academy, we are actively transforming the way we educate our customers around the world by surrounding them with cutting-edge technology, clinical content and scientific data.”

A number of VR educational modules are currently available, including the world’s first for arthroscopic meniscal repair launched earlier this year. Additionally, a module for JOURNEY II BCS total knee arthroplasty using robot-assisted CORI Surgical System will be launched worldwide in October.

If you are a healthcare professional and would like to learn more about Smith+Nephew’s world-class medical education offerings, please visit our booth at OSET (#110) and our global Education Unlimited platform https://educationunlimited.smith-nephew.com/

References
1. Blumstein G, Zukotynski B, Cevallos N, et al. Randomized trial of a virtual reality tool to teach surgical technique for intramedullary nailing of tibial stem fractures. J Surgery. 2020;77(4):969–977
2. Results of Smith+Nephew investigation on file

About Smith+Neveu
Smith+Nephew is a portfolio medical technology company focused on hard and soft tissue repair, regeneration and replacement. We exist to restore people’s bodies and their self-confidence by using technology to push the limits of life. We call this goal ‘Life Unlimited’. Our 18,000 employees carry out this mission every day, making a difference in the lives of patients through the excellence of our product portfolio, as well as the invention and application of new technologies in our three global orthopedics, sports and ENT medicine and advanced wound management franchises.

Founded in Hull, United Kingdomin 1856, we now operate in over 100 countries and generate annual sales of $5.2 billion in 2021. Smith+Nephew is part of the FTSE100 (LSE: SN, NYSE:SNN). The terms “Group” and “Smith+Nephew” are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context otherwise requires.

For more information about Smith+Nephew, please visit www.smith-
nephew.com
and follow us on Twitter, LinkedIn, instagram Where Facebook.

Forward-looking statements
This document may contain forward-looking statements which may or may not prove to be accurate. For example, statements regarding expected revenue and trading margin growth, market trends and our product portfolio are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well placed”, “believe”, “estimate”, “expect”, “target”, “consider ” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the magnitude and duration of its impact, government actions and other restrictive measures taken in response, significant delays and cancellations elective procedures, reduced procedural capacity at medical facilities, restricted access of sales representatives to medical facilities, or our ability to execute business continuity plans due to COVID-19; economic and financial conditions in the markets we serve, particularly those affecting healthcare providers, payers and customers (including, without limitation, as a result of COVID-19); price levels of established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other governmental actions; product defects or recalls or other issues with quality management systems or non-compliance with related regulations; disputes relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including without limitation as a result of COVID-19); competitions for qualified personnel; strategic actions, including acquisitions and divestitures, our success in performing due diligence, evaluation and integration of acquired businesses; disruptions that may result from transactions or other changes we make to our business plans or organization to adapt to market changes; and many other matters that affect us or our markets, including those of a political, economic, commercial, competitive or reputational nature. Please refer to the documents Smith+Nephew has filed with the United States Securities and Exchange Commission under the United States Securities Exchange Act of 1934, as amended, including Smith+Nephew’s latest annual report on Form 20-F, for a discussion of some of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this cautionary statement. Smith+Nephew undertakes no obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew’s expectations.

Trademark of Smith+Nephew. Certain marks are registered in the US Patent and Trademark Office.

SOURCESmith & Nephew plc


[ad_2]
Source link

Share.

Comments are closed.